KDR and neoplasm: Instead, T cells have been engineered to target tumor-associated endothelial receptors such as VEGFR2 to disrupt tumor-supporting vasculature, enhance T cell trafficking, and deprive the tumor of nutrient and oxygen supplies [15,16].